BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 35854236)

  • 21. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
    Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 study.
    Tu H; Huang H; Ouyang Y; Liu Q; Xian B; Song K; Chen G; Shen Y; Liu J
    Int J Gynecol Cancer; 2021 Jan; 31(1):129-133. PubMed ID: 32522771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
    Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer.
    Li J; Li Y; Wang H; Shen L; Wang Q; Shao S; Shen Y; Xu H; Liu H; Cai R; Feng W
    BMC Cancer; 2023 Jan; 23(1):51. PubMed ID: 36641433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Definitive concurrent chemoradiotherapy in cervical cancer--a University of Malaya Medical Centre experience.
    Zamaniah WI; Mastura MY; Phua CE; Adlinda A; Marniza S; Rozita AM
    Asian Pac J Cancer Prev; 2014; 15(20):8987-92. PubMed ID: 25374241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
    Zhang MQ; Liu SP; Wang XE
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):821-7. PubMed ID: 20207507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
    O'Malley DM; Neffa M; Monk BJ; Melkadze T; Huang M; Kryzhanivska A; Bulat I; Meniawy TM; Bagameri A; Wang EW; Doger de Speville Uribe B; Hegg R; Ortuzar Feliu W; Ancukiewicz M; Lugowska I
    J Clin Oncol; 2022 Mar; 40(7):762-771. PubMed ID: 34932394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
    Kaira K; Mouri A; Kato S; Yoshimura K; Kagamu H; Kobayashi K
    BMC Cancer; 2020 Oct; 20(1):961. PubMed ID: 33023530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer.
    Wang S; Zhang DS; Pan T; Liu S; Wang MK
    Chin J Cancer; 2010 Nov; 29(11):959-63. PubMed ID: 20979696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
    Mayadev J; Zamarin D; Deng W; Lankes H; O'Cearbhaill R; Aghajanian CA; Schilder R
    Int J Gynecol Cancer; 2020 May; 30(5):701-704. PubMed ID: 31871115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
    Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
    Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer.
    Miglietta L; Franzone P; Centurioni MG; Boni L; Tacchini L; Cosso M; Boccardo F; Ferrarini M; Bruzzone M
    Oncology; 2006; 70(1):19-24. PubMed ID: 16439862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
    Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
    Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
    Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
    Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.
    Tangjitgamol S; Tharavichitkul E; Tovanabutra C; Rongsriyam K; Asakij T; Paengchit K; Sukhaboon J; Penpattanagul S; Kridakara A; Hanprasertpong J; Chomprasert K; Wanglikitkoon S; Atjimakul T; Pariyawateekul P; Katanyoo K; Tanprasert P; Janweerachai W; Sangthawan D; Khunnarong J; Chottetanaprasith T; Supawattanabodee B; Lertsanguansinchai P; Srisomboon J; Isaranuwatchai W; Lorvidhaya V
    J Gynecol Oncol; 2019 Jul; 30(4):e82. PubMed ID: 31074236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.